Oracle Completes Acquisition of MICROS Systems REDWOOD

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Oracle Completes Acquisition of MICROS Systems

REDWOOD SHORES, CA--(Marketwired - Sep 8, 2014) - Oracle ( NYSE : ORCL )

The combination of Oracle and MICROS will help Hotels, Food & Beverage (F&B) and Retail companies transform their businesses and compete more effectively in today's environment. Oracle will continue its highly successful dedicated business unit model with MICROS by creating a new Hospitality Global Business Unit focused on the Hotel and F&B industry. This new unit will be led by Mike Webster, Oracle's existing head of the Oracle Retail Global Business Unit.

"Together, Oracle and MICROS will help Hospitality and Retail companies respond to rapidly evolving customer expectations, increase revenue, and drive operational improvements with complete, open and integrated solutions," said Mike Webster, Senior Vice President and GM, Oracle Retail and Hospitality. "Our customers will appreciate our deep domain expertise across both Retail and Hospitality as we deliver mission-critical solutions to solve our customers' most important business initiatives." 

More information about this announcement is available at oracle.com/micros

Supporting Resources

About Oracle Oracle engineers hardware and software to work together in the cloud and in your data center. For more information about Oracle ( NYSE : ORCL ), visit www.oracle.com .

Trademarks Oracle is a registered trademark of Oracle Corporation and/or its affiliates. Other names may be trademarks of their respective owners.

Cautionary Statement Regarding Forward-Looking Statements

This document contains certain forward-looking statements about Oracle and MICROS, including statements that involve risks and uncertainties concerning Oracle's acquisition of MICROS, anticipated customer benefits and general business outlook. When used in this document, the words "anticipates", "can", "will", "look forward to", "expected" and similar expressions and any other statements that are not historical facts are intended to identify those assertions as forward-looking statements. Any such statement may be influenced by a variety of factors, many of which are beyond the control of Oracle or MICROS, that could cause actual outcomes and results to be materially different from those projected, described, expressed or implied in this document due to a number of risks and uncertainties. Potential risks and uncertainties include, among others, the risk that anticipated synergies of the combined companies may not be achieved after closing, the combined operations may not be successfully integrated in a timely manner, if at all, general economic conditions in regions in which either companies do business, and the possibility that Oracle or MICROS may be adversely affected by other economic, business, and/or competitive factors. Accordingly, no assurances can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do so, what impact they will have on the results of operations or financial condition of Oracle or MICROS.

In addition, please refer to the documents that Oracle and MICROS, respectively, file with the U.S. Securities and Exchange Commission (the "SEC") on Forms 10-K, 10-Q and 8-K. These filings identify and address other important factors that could cause Oracle's and MICROS' respective operational and other results to differ materially from those contained in the forward-looking statements set forth in this document. You are cautioned to not place undue reliance on forward-looking statements, which speak only as of the date of this document. Neither Oracle nor MICROS is under any duty to update any of the information in this document.

Oracle is currently reviewing the existing MICROS product roadmap and will be providing guidance to customers in accordance with Oracle's standard product communication policies. Any resulting features and timing of release of such features as determined by Oracle's review of MICROS' product roadmap are at the sole discretion of Oracle. All product roadmap information, whether communicated by MICROS or by Oracle, does not represent a commitment to deliver any material, code, or functionality, and should not be relied upon in making purchasing decisions. It is intended for information purposes only, and may not be incorporated into any contract.

Contact Info Deborah Hellinger Oracle Corporate Communications +1.212. 508.7935 Email Contact Ken Bond Oracle Investor Relations +1.650.607.0349 Email Contact

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Voter Events by Valley Community Healthcare Aim to Empower

Updated Category News Views 39

Here's a game-changer for the community. Valley Community Healthcare (VCH) is stepping up, proving that healthcare doesn't just stick to check-ups and prescriptions. It's about the whole shebang—community empowerment included. This October, VCH is hosting two incredible voter events, collaborating with the Los Angeles County Registrar-Recorder's Mobile Voting Program....

Continue Reading
Weifang's Cultural Resurgence: A Global Epigraphy Fest

Updated Category News Views 46

A Historical Meltdown into Global Recognition Welcome to the ride where ancient stones talk and cultural borders vanish. We're diving into the beating heart of Weifang, a place you're probably hearing about now because the town's hosting a packed international media tour. And, for a change, this isn't just another tourist trap; it's a cultural adrenaline shot to the arm,...

Continue Reading
AEVEX Facing Class Action Deadline Amid Stock Turmoil

Updated Category News Views 48

Investors are no strangers to the rough and tumble of stock markets, but things get downright messy when trust is shattered. That's the sorry saga unfolding with AEVEX, where shareholders are feeling the heat after a sharp nosedive in stock value. The clock is ticking to join the class action, and any AEVEX investor worth their salt should pay attention. Unraveling...

Continue Reading
Masimo's smartSET™ Revolutionizes Patient Monitoring

Updated Category News Views 44

Breaking Ground in Patient Monitoring Let's dive into the gritty details behind Masimo's latest FDA-nod: the smartSET™ system. This gizmo ain't your ordinary pulse oximeter; it's a next-gen hand-holder for the medical world, poised to ride the AI wave straight into the clinic. They've cracked open a new way for clinicians to peek behind the curtain of patient vitals,...

Continue Reading
LG OLED evo W6: UAE Roadshow Starts with a Bang

Updated Category News Views 50

They've done it again, folks. LG Electronics is out there kicking up a storm with their all-new OLED evo W6 True Wireless Wallpaper TV, and they're bringing the action straight to the UAE's doorsteps. Imagine taking a stroll and stumbling upon this technological marvel at some fancy spot like The Lotus Lounge at Anantara The Palm Dubai Resort. This ain't just a TV, it's a...

Continue Reading
Innventure Faces Major Lawsuit Over Misleading Investors

Updated Category News Views 61

Missteps at Innventure: A Costly Lesson in Investor Trust The stock market is no stranger to drama, but Innventure's saga feels like a page ripped right out of a thriller novel. You’ve got accusations, alleged fabrications, and a swift drop in stock prices that’s left some investors shaking their heads. The company, nestled under the ticker NASDAQ:INV, finds itself...

Continue Reading
Hyliion Class Action Deadline Nears for Investors

Updated Category News Views 58

Potential Shockwaves for Hyliion Investors Investors are having a showdown with Hyliion (NYSE:HYLN) these days. With the looming October 27, 2026, deadline to jump into a securities class action, it seems Hyliion's latest escapade smells worse than a fish market on a hot day. We’ve got allegations here stronger than your uncle’s morning coffee. Understanding the Legal...

Continue Reading

Top 5 Most Recently Viewed Articles

Cemtrex's Stock Surge Sparks Interest in Leading Movers

Updated Category News Views 117

Cemtrex Experiences Notable Share Surge Shares of Cemtrex, Inc. CETX have seen a significant uptick amid pre-market trading. This boost comes on the heels of better-than-expected sales in the latest quarter, reporting an impressive $18.10 million in sales, surpassing the general analyst expectation of $16.39 million. This remarkable performance in sales has sparked...

Continue Reading
Exciting New PharmD-MBA Pathway Combines Pharmacy and Business

Updated Category News Views 193

Collaboration between Cal Poly Pomona and Western University In an exciting move, Cal Poly Pomona's Singelyn Graduate School of Business and Western University of Health Sciences have teamed up to create a groundbreaking pathway for aspiring healthcare professionals. This innovative PharmD-MBA program combines the fields of pharmacy and business, providing a unique...

Continue Reading
Kaskela Law Investigates Stock Misconduct in Stanley Black & Decker

Updated Category News Views 155

Overview of the Investigation by Kaskela Law LLC Kaskela Law LLC has announced an important investigation focused on Stanley Black & Decker, Inc. (NYSE: SWK) concerning allegations of potential securities fraud. This inquiry is primarily aimed at safeguarding the interests of long-term investors who hold shares in this well-known manufacturing company. Details Surrounding...

Continue Reading
Legend Biotech's Carvykti: A Leading Force in Cancer Treatment

Updated Category News Views 90

Redburn's Positive Outlook for Legend Biotech Recently, Redburn-Atlantic began covering Legend Biotech Corp. (NASDAQ: LEGN) with a favorable Buy rating and set a price target of $86.00 for the stock. This biotechnology company has made significant strides, particularly with the recent approval of its innovative product, Carvykti, designed for the treatment of multiple...

Continue Reading
Transforming the Anti-Obesity Drug Market for Future Success

Updated Category News Views 132

Global Anti-Obesity Drug Market Overview As global health concerns rise, the demand for anti-obesity drugs is surging. Recent reports estimate that the anti-obesity drug market will soar to USD 82.55 billion in the coming years. This impressive growth, fueled by an anticipated compound annual growth rate (CAGR) of 18.01%, signals a crucial moment for pharmaceutical...

Continue Reading